A subscription to JoVE is required to view this content. Sign in or start your free trial.

Research Article

N-Lactoyl-phenylalanine Improves Cardiac Function in a Mouse Model of Diabetic Cardiomyopathy by Regulating Lipid Metabolism

151 views

⸱

DOI:

10.3791/72633

⸱

September 1st, 2026

 ,  ,  ,  ,  ,  , 

Corresponding Authors: Shaojun Wu <sjwu@cmu.edu.cn>, Rong Gu <gurong.nju@163.com>

In This Article

Summary

This protocol describes in vivo and in vitro approaches to investigate how N-lactoyl-phenylalanine affects diabetic cardiomyopathy, cardiac lipid metabolism, and cholesterol synthesis, with a focus on the adenosine monophosphate-activated protein kinase alpha 1/3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway.

Abstract

Diabetic cardiomyopathy (DCM) is one of the most serious complications of diabetes. N-lactoyl-phenylalanine (Lac-Phe), an endogenous metabolite, can promote weight loss and improve glucose homeostasis. This study sought to investigate the therapeutic effect of Lac-Phe on DCM and further explore the underlying mechanism. Type 2 diabetic mice with DCM were treated with Lac-Phe. Lac-Phe enhanced cardiac contractile function, ameliorated pathological remodeling, and reduced lipid accumulation in the heart. In vitro, the effects of Lac-Phe were investigated in H9c2 cells stimulated with high glucose and palmitic acid. Lac-Phe reduced lipid accumulation by decreasing cholesterol synthesis in H9c2 cells. Mechanistically, Lac-Phe promoted the phosphorylation and activation of adenosine monophosphate-activated protein kinase alpha 1 (AMPKα1). Subsequently, activated AMPKα1 phosphorylated and inhibited its downstream target, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), leading to reduced cholesterol synthesis and ultimately ameliorating lipid metabolism imbalance in H9c2 cells. These findings indicate that Lac-Phe improves lipid metabolism in H9c2 cells in DCM through the AMPKα1/HMGCR pathway, thereby enhancing cardiac contractile function and ameliorating pathological remodeling. Lac-Phe may represent a potential therapeutic approach for diabetic cardiomyopathy.

Introduction

Diabetes is a metabolic disease characterized by persistent hyperglycemia1. Over the past two decades, diabetes has become one of the top ten causes of death worldwide, with more than six million people dying from diabetes and its complications each year2. Diabetic cardiomyopathy (DCM), a cardiac pathological condition resulting from diabetes, represents one of the most severe complications associated with diabetes3,4. It functions as an independent risk factor for heart failure and is characterized by structural and functional myocardial alterations

Access restricted. Please log in or start a trial to view this content.

Protocol

The animal study protocol was approved by the Institutional Ethics Committee of Nanjing Drum Tower Hospital (Approval Number: 2025AE1065, 26 September 2025) and was conducted in accordance with the guidelines outlined in the Guidelines for the Care and Use of Laboratory Animals (8th Edition), published by the National Institutes of Health of the United States.

Animals

Thirty 5-week-old male C57BL/6J mice were used in this study. After 1 week of adaptive feeding, all mice were housed with access to food and water under an alternating 12 h day-night cycle at a temperature of 22°C ± 2°C and....

Access restricted. Please log in or start a trial to view this content.

Results

Lac-Phe improves cardiac function in diabetic cardiomyopathy mice

We induced DCM in C57BL/6J mice using an HFD combined with STZ injections (Figure 1A) and randomly assigned the successfully established DCM mice to an untreated group (DCM group) and a Lac-Phe treatment group, with control C57BL/6J mice serving as the negative control. According to the study by Li et al.21, we selected 50 mg/kg as the therapeutic dose of Lac.......

Access restricted. Please log in or start a trial to view this content.

Discussion

In this study, we provide evidence supporting a therapeutic effect of Lac-Phe on DCM. Lac-Phe improved cardiac remodeling and cardiac dysfunction in DCM while reducing cholesterol production in cardiomyocytes and ameliorating lipid metabolism imbalance. Mechanistically, Lac-Phe increased AMPKα1 phosphorylation. Subsequently, increased AMPKα1 phosphorylation was associated with increased phosphorylation and inhibition of its downstream target HMGCR, leading to a reduction in cholesterol synthesis and ultimately .......

Access restricted. Please log in or start a trial to view this content.

Disclosures

Conflict of Interest:

The authors have nothing to disclose.

Acknowledgements

We would like to express our sincere gratitude to the researchers and staff at the Nanjing Drum Tower Hospital Clinical College and the Affiliated Hospital of Medical School, Nanjing University, for their technical support. This research was funded by grants from the National Natural Science Foundation of China (Grant Nos. 81870291 and 82300384), the China Postdoctoral Science Foundation (Grant No. 2023M731625), and the Natural Science Foundation of Jiangsu Province (Grant No. BK20220175). We also appreciate the resources and collaborative support provided by the Institute of Advanced Synthesis at Nanjing Tech University.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
AMPK-IN-3 (p-AMPK inhibitor)MedChemExpress (MCE)HY-132921Used at 10 μM during AMPK inhibition experiments to inhibit AMPK signaling in Lac-Phe-treated cells.
Amplex Red Cholesterol and Cholesteryl Ester Assay KitBeyotimeS0211SUsed to determine total cholesterol levels in serum and H9c2 cell samples.
Anti-AMPKα1Cell Signaling Technology2532; RRID: AB_330331Primary antibody used for western blot analysis of AMPKα1.
Anti-GAPDHCell Signaling Technology5174; RRID: AB_10622025Primary antibody used for western blot analysis of GAPDH.
Anti-HMGCRAbcamab174830; RRID: AB_2749818Primary antibody used for western blot analysis of HMGCR.
Anti-p-AMPKα1 (Thr172)Cell Signaling Technology2535; RRID: AB_331250Primary antibody used for western blot analysis of phosphorylated AMPKα1.
Anti-p-HMGCR (Ser872)Abcamab124350Primary antibody used for western blot analysis of phosphorylated HMGCR.
Anti-rabbit IgG, HRP-linked antibodyCell Signaling Technology7074; RRID: AB_2099233Used at 1:5,000 dilution for western blot detection.
Anti-β-tubulinCell Signaling Technology2128; RRID: AB_823664Primary antibody used for western blot analysis of β-tubulin.
AtorvastatinMedChemExpress (MCE)HY-17379Used alone or in combination with Lac-Phe to assess effects on lipid accumulation, total cholesterol levels, and HMGCR phosphorylation in HG/PA-treated H9c2 cells.
Bovine serum albuminSigma-AldrichA7906Used at 5% to block nonspecific binding during western blot analysis.
Bradford assay reagent/kitThermo Fisher Scientific23200Used to determine protein concentration before western blot analysis.
C57BL/6J mice (5-week-old, male)Model Animal Research Center of Nanjing UniversityN/AUsed to establish the HFD/STZ-induced diabetic cardiomyopathy mouse model.
Cell Counting Kit-8 (CCK-8)SharebioSB-CCK8SUsed to measure H9c2 cell viability following treatment.
Citrate bufferPrepared in-houseN/APrepared at pH 4.5 and used to dissolve STZ and as the corresponding vehicle control.
Control diet (10% fat, 20% protein, 70% carbohydrate)Research Diets, Inc.D12450JUsed as the diet for control-group mice.
D-(+)-GlucoseSigma-AldrichN/AUsed for HG/PA cell treatment and for the oral glucose tolerance test.
Dimethyl sulfoxide (DMSO)Sigma-AldrichD2650Used as the solvent for AMPK-IN-3 and as the corresponding vehicle control.
Dulbecco’s modified Eagle’s mediumGibco, Thermo Fisher Scientific11965092Used as the basal culture medium for H9c2 cells.
Echocardiography machine with 40 MHz transducerFUJIFILM VisualSonicsVevo 3100 LT; 40 MHz transducerUsed to measure left ventricular dimensions and mitral valve blood flow velocity and to derive LVEF and FS.
Electron microscope fixativeServiceBioG1102Used to fix fresh mouse heart tissue for transmission electron microscopy.
EthanolSigma-AldrichE7023Used in progressively increasing concentrations for dehydration during transmission electron microscopy sample preparation.
Fetal bovine serumGibco, Thermo Fisher Scientific10099141Used at 10% to supplement H9c2 cell culture medium.
H9c2 cell lineSunncellRRID: CVCL_0286Used as the in vitro cardiac cell model for HG/PA and Lac-Phe treatment experiments.
Hematoxylin and eosin stainServiceBioG1005-1/2Used for histological assessment of cardiac tissue.
High-fat diet (60 kcal% fat)Research Diets, Inc.D12492Used with low-dose STZ to establish the diabetic cardiomyopathy mouse model.
High-resolution brightfield microscopeLeicaDM2500Used for whole-slide imaging of stained cardiac tissue at 20× magnification.
ImageJNational Institutes of HealthN/AUsed for densitometric quantification of western blot results.
IsofluraneSigma-Aldrich792632Used for anesthesia during mouse echocardiography.
Isopropyl alcoholSigma-AldrichI9516Used at 60% during Oil Red O staining of frozen cardiac sections.
LD540 lipid stainBeyotimeC2050S-1Used at 10 μM to stain intracellular lipids.
Masson’s trichrome stainServiceBioG1006Used for histological staining of cardiac tissue.
N-lactoyl-phenylalanine (Lac-Phe)MedChemExpress (MCE)HY-146098Administered to DCM mice and used to treat HG/PA-exposed H9c2 cells.
Oil Red O working solutionServiceBioG1015-100MLUsed to stain lipids in frozen cardiac tissue sections.
Omni-ECL Efficient Light Chemiluminescence KitEpiZymeSQ203LUsed for chemiluminescent visualization of protein bands after western blotting.
Palmitic acidSigma-AldrichP0500Used at 0.25 mM with high glucose to establish the HG/PA-treated H9c2 cell model.
ParaformaldehydeSigma-AldrichP6148Prepared as a 4% solution and used to fix cardiac tissue and cells before histological or lipid staining.
Penicillin-streptomycinGibco, Thermo Fisher Scientific15140122Used at 1% in H9c2 cell culture medium.
Phosphate-buffered saline (PBS)Gibco, Thermo Fisher Scientific10010023Used for washing during staining procedures and as the corresponding vehicle in cell-treatment experiments.
PrismGraphPad SoftwareVersion 8.0Used for statistical analysis of experimental data.
PVDF transfer membrane, 0.45 μmThermo Fisher Scientific88518Used for electrophoretic transfer of proteins during western blot analysis.
RNeasy Mini KitQIAGEN74104Used for isolation/purification of total RNA from mouse cardiac tissue.
Sodium chloride solution, 0.9% (normal saline)Sigma-AldrichS8776Used to dissolve Lac-Phe and as the vehicle control for Control and DCM mice.
SPSSIBMVersion 20.0Used for statistical analysis of experimental data.
Streptozotocin (STZ)Sigma-AldrichS0130Administered with HFD feeding to establish the diabetic cardiomyopathy mouse model.
TBS Tween-20 Buffer (20×)Thermo Fisher Scientific28360Used to wash membranes after primary- and secondary-antibody incubation during western blot analysis.
Tissue-Tek O.C.T. CompoundSakura Finetek4583Used to embed cardiac tissue before preparation of frozen sections for Oil Red O staining.
Transmission electron microscopeHITACHIHT7800Used to examine ultrastructural changes in mouse cardiac tissue.
TRIzol ReagentInvitrogen15596026Used for total RNA isolation from mouse cardiac tissue.
VAHTS Universal V10 RNA-seq Library Prep KitVazymeNR616-01Used to prepare RNA-seq libraries for transcriptomic analysis.
Wheat germ agglutinin (WGA)ServiceBioW7024Used for histological assessment of cardiac tissue.

References

  1. Pan KL, Hsu YC, Chang ST, Chung CM, Lin CL. The role of cardiac fibrosis in diabetic cardiomyopathy: from pathophysiology to clinical diagnostic tools. Int J Mol Sci. 2023;24(10):8604.
  2. Saeedi P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
  3. Zou R, et al. PGAM5-mediated PHB2 dephosphorylation contributes to diabetic cardiomyopathy by disrupting mitochondrial quality surveillance. Research. 2022;2022:0001.
  4. Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in d....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Cholesterol SynthesisAMPK ActivationHMGCR InhibitionPathological RemodelingGlucose Homeostasis

This article has been published

Video Coming Soon